» Articles » PMID: 25821874

Community-wide Measures of Wellness in a Remote First Nations Community Experiencing Opioid Dependence: Evaluating Outpatient Buprenorphine-naloxone Substitution Therapy in the Context of a First Nations Healing Program

Overview
Date 2015 Mar 31
PMID 25821874
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To document the development of unique opioid-dependence treatment in remote communities that combines First Nations healing strategies and substitution therapy with buprenorphine-naloxone.

Design: Quantitative measurements of community wellness and response to community-based opioid-dependence treatment.

Setting: Remote First Nations community in northwestern Ontario.

Participants: A total of 140 self-referred opioid-dependent community members.

Intervention: Community-developed program of First Nations healing, addiction treatment, and substitution therapy.

Main Outcome Measures: Community-wide measures of wellness: number of criminal charges, addiction-related medical evacuations, child protection agency cases, school attendance, and attendance at community events.

Results: The age-adjusted adult rate of opioid-dependence treatment was 41%. One year after the development of the in-community healing and substitution therapy program for opioid dependence, police criminal charges had fallen by 61.1%, child protection cases had fallen by 58.3%, school attendance had increased by 33.3%, and seasonal influenza immunizations had dramatically gone up by 350.0%. Attendance at community events is now robust, and sales at the local general store have gone up almost 20%.

Conclusion: Community-wide wellness measures have undergone dramatic public health changes since the development of a First Nations healing program involving opioid substitution therapy with buprenorphine-naloxone. Funding for such programs is ad hoc and temporary, and this threatens the survival of the described program and other such programs developing in this region, which has been strongly affected by an opioid-dependence epidemic.

Citing Articles

Culturally tailored substance use interventions for Indigenous people of North America: a systematic review.

Richer A, Roddy A J Ment Health Train Educ Pract. 2023; 18(1):60-77.

PMID: 37292247 PMC: 10248734. DOI: 10.1108/jmhtep-07-2021-0088.


A realist review of best practices and contextual factors enhancing treatment of opioid dependence in Indigenous contexts.

Henderson R, McInnes A, Danyluk A, Wadsworth I, Healy B, Crowshoe L Harm Reduct J. 2023; 20(1):34.

PMID: 36932417 PMC: 10022548. DOI: 10.1186/s12954-023-00740-x.


A scoping review of opioid harm reduction interventions for equity-deserving populations.

Milaney K, Haines-Saah R, Farkas B, Egunsola O, Mastikhina L, Brown S Lancet Reg Health Am. 2023; 12:100271.

PMID: 36776426 PMC: 9904129. DOI: 10.1016/j.lana.2022.100271.


A collaborative approach to hepatitis C testing in two First Nations communities of northwest Ontario.

Smookler D, Beck A, Head B, Quoquat L, Albany C, Farrell T Can Liver J. 2022; 5(3):329-338.

PMID: 36133895 PMC: 9473560. DOI: 10.3138/canlivj-2021-0031.


Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: an integrative review.

Pijl E, Alraja A, Duff E, Cooke C, Dash S, Nayak N Subst Abuse Treat Prev Policy. 2022; 17(1):62.

PMID: 36028837 PMC: 9412807. DOI: 10.1186/s13011-022-00463-5.


References
1.
Sohler N, Li X, Kunins H, Sacajiu G, Giovanniello A, Whitley S . Home- versus office-based buprenorphine inductions for opioid-dependent patients. J Subst Abuse Treat. 2009; 38(2):153-9. PMC: 2849656. DOI: 10.1016/j.jsat.2009.08.001. View

2.
Fudala P, Bridge T, Herbert S, Williford W, Chiang C, Jones K . Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003; 349(10):949-58. DOI: 10.1056/NEJMoa022164. View

3.
Mintzer I, Eisenberg M, Terra M, MacVane C, Himmelstein D, Woolhandler S . Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med. 2007; 5(2):146-50. PMC: 1838690. DOI: 10.1370/afm.665. View

4.
Lee J, Grossman E, DiRocco D, Gourevitch M . Home buprenorphine/naloxone induction in primary care. J Gen Intern Med. 2008; 24(2):226-32. PMC: 2628995. DOI: 10.1007/s11606-008-0866-8. View

5.
Dhalla I, Mamdani M, Sivilotti M, Kopp A, Qureshi O, Juurlink D . Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ. 2009; 181(12):891-6. PMC: 2789126. DOI: 10.1503/cmaj.090784. View